IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens

Blood

Volumn 124, Issue 24, 2014, Pages 3561-3571

  Maglione, Paul J ^a   Simchoni, Noa ^a   Black, Samuel ^a   Radigan, Lin ^a   Overbey, Jessica R ^a   Bagiella, Emilia ^a   Bussel, James B ^b   Bossuyt, Xavier ^c   Casanova, Jean Laurent ^e,g   Meyts, Isabelle ^c,d   Cerutti, Andrea ^a   Picard, Capucine ^e,f,g   Cunningham Rundles, Charlotte ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e IMAGINE INSTITUTE   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CD27 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; PNEUMOCOCCUS VACCINE; T INDEPENDENT BACTERIAL ANTIGEN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK4 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CELL STIMULATION; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; LYMPHOCYTE SUBPOPULATION; MALE; NONHUMAN; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; ANIMAL; BACTERIAL INFECTION; CELL CULTURE; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; INFANT; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL INFECTIONS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MALE; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; POLYSACCHARIDES, BACTERIAL; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 84915745723     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-587824     Document Type: Article

References (66)

1. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299(5615):2076-2079.
2. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321(5889):691-696.
3. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore). 2010;89(6):403-425.
4. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
5. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol. 2010;11(9):836-845.
6. Almejun MB, Cols M, Zelazko M, et al. Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. Eur J Immunol. 2013;43(3):805-814.
7. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med. 2007;204(10):2407-2422.
8. + B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood. 2012;120(25):4992-5001.
9. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104(12):3647-3654.
10. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol. 2013;13(2):118-132.
11. Frasch CE, Concepcion NF. Specificity of human antibodies reactive with pneumococcal C polysaccharide. Infect Immun. 2000;68(4):2333-2337.
12. Weidenmaier C, Peschel A. Teichoic acids and related cell-wall glycopolymers in gram-positive physiology and host interactions. Nat Rev Microbiol. 2008;6(4):276-287.
13. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001;14(5):617-629.
14. Moens L, Jeurissen A, Wuyts G, et al. Specific intracellular adhesion molecule-grabbing nonintegrin R1 is not involved in the murine antibody response to pneumococcal polysaccharides. Infect Immun. 2007;75(12):5748-5752.
15. Koppel EA, Wieland CW, van den Berg VC, et al. Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection. Eur J Immunol. 2005;35(10):2962-2969.
16. Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med. 1981;153(3):694-705.
17. Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol. 2002;168(12):6375-6381.
18. Wallick S, Claflin JL, Briles DE. Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol. 1983;130(6):2871-2875.
19. Yother J, Forman C, Gray BM, Briles DE. Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun. 1982;36(1):184-188.
20. Ekdahl K, Braconier JH, Svanborg C. Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection. Clin Infect Dis. 1997;25(3):654-660.
21. Goldenberg HB, McCool TL, Weiser JN. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis. 2004;190(7):1254-1263.
22. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197(7):939-945.
23. Blixt O, Head S, Mondala T, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 2004;101(49):17033-17038.
24. Cholleti SR, Agravat S, Morris T, et al. Automated motif discovery from glycan array data. OMICS. 2012;16(10):497-512.
25. Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun. 1990;58(12):3871-3876.
26. Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis. 1990;161(4):736-740.
27. Vitharsson G, Jónsdóttir I, Jónsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis. 1994;170(3):592-599.
28. Carsetti R, Pantosti A, Quinti I. Impairment of the antipolysaccharide response in splenectomized patients is due to the lack of immunoglobulin M memory B cells. J Infect Dis. 2006;193(8):1189-1190.
29. Wasserstrom H, Bussel J, Lim LC, Cunningham-Rundles C. Memory B cells and pneumococcal antibody after splenectomy. J Immunol. 2008;181(5):3684-3689.
30. Sørensen UB, Henrichsen J. C-polysaccharide in a pneumococcal vaccine. Acta Pathol Microbiol Immunol Scand [C]. 1984;92(6):351-356.
31. Tam FC, Ma CH, Leung DT, Sutton B, Lim PL. Carrier-specificity of a phosphorylcholine-binding antibody requires the presence of the constant domains and is not dependent on the unique VH49 glycine or VH30 threonine residues. J Immunol Methods. 2007;321(1-2):152-163.
32. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-S194.
33. González-Fernández A, Faro J, Fernández C. Immune responses to polysaccharides: lessons from humans and mice. Vaccine. 2008;26(3):292-300.
34. Ku CL, Picard C, Erdös M, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet. 2007;44(1):16-23.
35. Borgers H, Moens L, Picard C, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010;134(2):198-205.
36. Tangye SG, Good KL. Human IgM1CD27+ B cells: memory B cells or "memory" B cells? J Immunol. 2007;179(1):13-19.
37. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev. 2011;24(3):490-497.
38. Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett. 2009;125(2):79-85.
39. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol. 2010;10(11):778-786.
40. Alugupalli KR, Akira S, Lien E, Leong JM. MyD88-and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses. J Immunol. 2007;178(6):3740-3749.
41. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180(2):800-808.
42. Khaskhely N, Mosakowski J, Thompson RS, Khuder S, Smithson SL, Westerink MA. Phenotypic analysis of pneumococcal polysaccharide-specific B cells. J Immunol. 2012;188(5):2455-2463.
43. Simell B, Nurkka A, Ekström N, Givon-Lavi N, Käyhty H, Dagan R. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol. 2012;19(10):1618-1623.
44. Baxendale HE, Johnson M, Stephens RC, et al. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol. 2008;151(1):51-60.
45. Micol R, Kayal S, Mahlaoui N, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol. 2012;129(3):770-777.
46. Gathmann B, Mahlaoui N, Gérard L, et al; CEREDIH; Dutch WID; European Society for Immunodeficiencies Registry Working Party. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-126.
47. Gustavsson ML, Gannedahl G, Bäcker AE, et al. Anti-carbohydrate antibodies associated with hyperacute rejection in a vascularized mouse heart-to-rat xenotransplantation model. Transplantation. 1996;61(6):957-963.
48. Aucouturier P, Berthier M, Bonneau D, Preud'homme JL. [Serum levels of IgG subclasses in the normal child. Evaluation by an immunoenzymatic method using monoclonal antibodies]. Arch Fr Pediatr. 1988;45(4):255-258.
49. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983;148(1):131-137.
50. Berlot G, Vassallo MC, Busetto N, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27(2):167-171.
51. Izdes S, Altintas ND, Eldem A, Ceyhan H, Kanbak O. Intravenous polyclonal IgM-enriched immunoglobulin therapy for resistant Acinetobacter sepsis in a pregnant patient with ARDS due to H1N1 infection. Int J Obstet Anesth. 2011;20(1):99-100.
52. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med. 1998;188(12):2381-2386.
53. Fabrizio K, Groner A, Boes M, Pirofski LA. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol. 2007;14(4):382-390.
54. Horn MP, Zuercher AW, Imboden MA, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010;54(6):2338-2344.
55. Louis AG, Gupta S. Primary selective IgM deficiency: an ignored immunodeficiency. Clin Rev Allergy Immunol. 2014;46(2):104-111.
56. Hong R, Gupta S. Selective immunoglobulin M deficiency in an adult with Streptococcus pneumoniae sepsis and invasive aspergillosis. J Investig Allergol Clin Immunol. 2008;18(3):214-218.
57. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36(4):810-816.
58. He B, Xu W, Santini PA, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26(6):812-826.
59. Xu W, Santini PA, Matthews AJ, et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol. 2008;181(1):276-287.
60. Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol. 2010;185(12):7293-7301.
61. Scheeren FA, Nagasawa M, Weijer K, et al. T cellindependent development and induction of somatic hypermutation in human IgM+ IgD+CD27+ B cells. J Exp Med. 2008;205(9):2033-2042.
62. Moens L, Wuyts M, Meyts I, De Boeck K, Bossuyt X. Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and antiprotein immune response. J Immunol. 2008;181(8):5306-5312.
63. Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol. 2009;182(2):890-901.
64. Guo F, Weih D, Meier E, Weih F. Constitutive alternative NF-kappaB signaling promotes marginal zone B-cell development but disrupts the marginal sinus and induces HEV-like structures in the spleen. Blood. 2007;110(7):2381-2389.
65. Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746-757.
66. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol. 2005;174(5):2942-2950.